SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism
SGLT2i use was associated with a greater suppression of myocardial glucose without affecting background tissue glycolysis despite higher prescan glucose levels. These findings add to the understanding of the effect of SGLT2i on the myocardium and may have implications with respect to cardiac imaging protocols that require glucose manipulation.
Authors
- Brett W. Sperry (ORCID: https://orcid.org/0000-0002-8210-6401)
- Andrew J. Sauer (ORCID: https://orcid.org/0000-0002-9268-2795)
- Ramy Ghaly (ORCID: https://orcid.org/0000-0002-1221-5864)
- Mohammad Abdel Jawad
- Yazan Almohtasib
- Timothy M. Bateman (ORCID: https://orcid.org/0009-0007-7959-6159)
Institutions
- Saint Luke's Health System (US)
- Saint Luke's Hospital (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102016
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29